NCT05792865

A Registry Study of Patients Hospitalized With Confirmed COVID-19

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 488 (estimated)
• Sponsor: Beijing Chao Yang Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The design of this registered study aims to evaluate the efficacy and safety of Paxlovid in the treatment of hospitalized COVID-19 patients, and to explore factors related to the efficacy and safety of Paxlovid.

Conditions

• COVID-19

Interventions

Type	Name	Description
DRUG	paxlovid	Patients treated with PAXLOVID within 5 days of being diagnosed with covid-19 will be included in this group. Patients treated with PAXLOVID will be included in this group. This study is a non-interventional observational study, and no intervention measures were applied to the clinical diagnosis and treatment process of hospitalized COVID-19 patients. The use of Paxlovid is completely decided by the clinical doctors based on the patients' condition and clinical experience.
DRUG	No paxlovid	Patients not treated with PAXLOVID will be included in this group. This study is a non-interventional observational study, and no intervention measures were applied to the clinical diagnosis and treatment process of hospitalized COVID-19 patients. The use of Paxlovid is completely decided by the clinical doctors based on the patients' condition and clinical experience.
DRUG	Paxlovid	Patients treated with PAXLOVID outside of the initial 5 days after being diagnosed with covid-19 will be included in this group.

Timeline

• Start date: 2023-03-30
• Primary completion: 2023-06-30
• Completion: 2023-12-30
• First posted: 2023-03-31
• Last updated: 2023-03-31

Regulatory

• FDA-regulated drug study